Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral Vector (FLT190) in Subjects With Fabry Disease

Next Previous
Trial Profile

A Multicenter, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral Vector (FLT190) in Subjects With Fabry Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FLT 190 (Primary)
  • Indications Fabry's disease
  • Focus Adverse reactions
  • Acronyms Marvel 2
  • Sponsors Freeline Therapeutics; Spur Therapeutics

Most Recent Events

  • 03 Sep 2026 Status changed to discontinued.
  • 17 Jun 2024 According to Freeline Therapeutics media release, Freeline Therapeutics has changed its name to Spur Therapeutics.
  • 21 Oct 2023 This trial has been discontinued in Germany according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top